Suppliers and packagers for generic pharmaceutical drug: PREDNISONE

PREDNISONE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	PREDNISONE	prednisone	SOLUTION;ORAL	088703	ANDA	Hikma Pharmaceuticals USA Inc.	0054-3722-50	120 mL in 1 BOTTLE (0054-3722-50)	1984-11-08
Hikma	PREDNISONE	prednisone	SOLUTION;ORAL	088703	ANDA	Hikma Pharmaceuticals USA Inc.	0054-3722-63	500 mL in 1 BOTTLE (0054-3722-63)	1984-11-08
Hikma	PREDNISONE	prednisone	SOLUTION;ORAL	088703	ANDA	Atlantic Biologicals Corps	17856-3722-1	5 mL in 1 CUP (17856-3722-1)	1986-12-13
Hikma	PREDNISONE INTENSOL	prednisone	SOLUTION;ORAL	088810	ANDA	Hikma Pharmaceuticals USA Inc.	0054-3721-44	30 mL in 1 BOTTLE, GLASS (0054-3721-44)	1985-02-20
Dr Reddys	PREDNISONE	prednisone	TABLET, DELAYED RELEASE;ORAL	219477	ANDA	Dr. Reddys Laboratories Inc.	43598-886-01	1 BOTTLE in 1 CARTON (43598-886-01) / 100 TABLET, DELAYED RELEASE in 1 BOTTLE	2025-12-15
Dr Reddys	PREDNISONE	prednisone	TABLET, DELAYED RELEASE;ORAL	219477	ANDA	Dr. Reddys Laboratories Inc.	43598-886-30	1 BOTTLE in 1 CARTON (43598-886-30) / 30 TABLET, DELAYED RELEASE in 1 BOTTLE	2025-12-15
Dr Reddys	PREDNISONE	prednisone	TABLET, DELAYED RELEASE;ORAL	219477	ANDA	Dr. Reddys Laboratories Inc.	43598-887-01	1 BOTTLE in 1 CARTON (43598-887-01) / 100 TABLET, DELAYED RELEASE in 1 BOTTLE	2025-12-15

Prednisone Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the global supply chain for prednisone, focusing on active pharmaceutical ingredient (API) manufacturers, key excipient providers, and regulatory considerations. The analysis identifies primary API suppliers, their production capacities, and geographic concentrations. It also examines the landscape of essential excipient manufacturing and the regulatory environment governing drug substance and product quality.

Who are the primary suppliers of prednisone API?

The global supply of prednisone active pharmaceutical ingredient (API) is concentrated among a limited number of manufacturers. These companies operate primarily in Asia, with India and China as the dominant production hubs.

Key prednisone API suppliers include:

• Alkem Laboratories Ltd. (India): A large Indian pharmaceutical company with significant API manufacturing capabilities. Alkem is a major producer of corticosteroids, including prednisone.
• Laurus Labs Ltd. (India): Another prominent Indian API manufacturer with a broad portfolio. Laurus Labs has established production lines for various active ingredients, including prednisone.
• Divi's Laboratories Ltd. (India): Known for its large-scale synthesis and custom manufacturing services, Divi's is a significant player in the API market for multiple therapeutic areas, including corticosteroids.
• Zhejiang NHU Co., Ltd. (China): A major Chinese producer of vitamins, nutritional ingredients, and pharmaceutical intermediates. NHU is involved in the manufacturing of various APIs, including those for anti-inflammatory drugs.
• Anhui Fengyuan Pharmaceutical Co., Ltd. (China): A Chinese chemical and pharmaceutical enterprise that manufactures a range of APIs and intermediates.

These manufacturers typically produce prednisone API in bulk quantities, supplying it to finished dosage form (FDF) manufacturers worldwide. Production capacity can vary, but these entities represent the primary source for a substantial portion of the global prednisone API requirement.

What is the production capacity and geographic concentration of prednisone API manufacturing?

Precise, real-time production capacities for specific APIs like prednisone are proprietary and not publicly disclosed by manufacturers. However, industry analysis indicates a significant concentration of prednisone API manufacturing in India and China.

• India: Represents approximately 30-40% of global generic API production [1]. Several large Indian pharmaceutical companies have dedicated facilities or significant capacity for steroid synthesis, a category that includes prednisone. These companies benefit from established expertise in complex organic synthesis, cost-effective labor, and robust supply chains for raw materials.
• China: Accounts for a substantial share of global API manufacturing, estimated at 20-30% [1]. Chinese manufacturers are known for their scale and ability to produce at competitive price points. Several chemical and pharmaceutical companies in China are equipped to synthesize prednisone API.

Other regions, such as Europe and North America, have some API manufacturing capabilities, but they are less dominant for high-volume generic APIs like prednisone due to higher operating costs and a strategic focus on more complex or niche molecules. The geographic concentration in India and China poses potential supply chain risks related to geopolitical factors, trade policies, and localized disruptions.

Which excipients are critical for prednisone drug formulations, and who supplies them?

Prednisone is typically formulated into oral solid dosage forms (tablets) and, less commonly, into injectable or topical formulations. Critical excipients are essential for drug dissolution, stability, compressibility, and overall product performance.

Common Excipients in Prednisone Tablets:

• Diluents/Fillers: Provide bulk to the tablet.
  • Lactose Monohydrate: Widely used. Suppliers include DMV-Fonterra Excipients (Netherlands), Foremost Farms USA, and various Asian manufacturers.
  • Microcrystalline Cellulose (MCC): Offers binding and disintegrant properties. Key suppliers include DuPont (USA) (formerly FMC Corporation), JRS Pharma (Germany), and Asahi Kasei (Japan).
  • Starch (Corn Starch, Potato Starch): Acts as a filler and binder. Suppliers include Tate & Lyle (UK), Cargill (USA), and Roquette Frères (France).
• Binders: Help to agglomerate the powder particles into granules during wet granulation, improving flow and compressibility.
  • Povidone (Polyvinylpyrrolidone, PVP): Common binder. Supplied by BASF (Germany) (under the Kollidon® brand), Ashland (USA), and Yoshi Chemicals (Japan).
  • Hydroxypropyl Methylcellulose (HPMC): Used as a binder and also for controlled release. Supplied by Dow (USA) (under the Methocel™ brand), Shin-Etsu Chemical (Japan), and Ashland (USA).
• Disintegrants: Promote tablet breakup after administration, facilitating drug dissolution.
  • Croscarmellose Sodium: A highly effective disintegrant. Supplied by DuPont (USA), Asahi Kasei (Japan), and JRS Pharma (Germany).
  • Sodium Starch Glycolate: Another common disintegrant. Supplied by JRS Pharma (Germany) and various other manufacturers.
• Lubricants: Reduce friction between the tablet and the die wall during compression.
  • Magnesium Stearate: The most common lubricant. Supplied by Mallinckrodt Pharmaceuticals (USA), Evonik Industries (Germany), and numerous global chemical suppliers.
  • Stearic Acid: Also used as a lubricant. Produced by major oleochemical companies.
• Glidants: Improve powder flow properties.
  • Colloidal Silicon Dioxide (Aerosil®): Enhances powder flow and prevents sticking. Supplied by Evonik Industries (Germany) and Cabot Corporation (USA).

The supply of these excipients is generally robust, with multiple global players. However, reliance on a few key suppliers for specialized excipients or for specific grades can introduce vulnerabilities. The pharmaceutical-grade excipient market is subject to stringent quality controls and regulatory oversight.

What are the regulatory requirements for prednisone API and finished drug products?

The manufacturing and quality of prednisone API and its finished dosage forms are governed by strict regulatory frameworks enforced by health authorities worldwide.

Key Regulatory Aspects:

• Good Manufacturing Practices (GMP): All facilities involved in the manufacturing of prednisone API and FDFs must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. GMP ensures consistent production and quality control.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit a DMF (in the US) or ASMF (in Europe) to regulatory authorities. These confidential documents contain detailed information about the API's manufacturing process, quality control, and stability. Drug product manufacturers can reference these filings in their marketing authorization applications.
• Pharmacopeial Standards: Prednisone API and finished products must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define acceptable limits for identity, purity, potency, and other critical quality attributes.
• Impurity Profiling: Regulatory agencies require thorough characterization and control of impurities in both API and FDF. This includes process-related impurities, degradation products, and residual solvents, with strict limits set for genotoxic impurities.
• Stability Testing: Manufacturers must conduct comprehensive stability studies to establish the shelf life of both the API and the finished drug product under various storage conditions, as per ICH (International Council for Harmonisation) guidelines.
• Facility Inspections: Regulatory authorities conduct routine inspections of manufacturing sites to ensure ongoing compliance with GMP. Non-compliance can lead to warning letters, import alerts, and market withdrawal.
• API Sourcing and Qualification: FDF manufacturers are responsible for qualifying their API suppliers, ensuring they meet all regulatory and quality requirements. This often involves audits of the API manufacturing sites.

The complexity of these regulations necessitates robust quality management systems and a deep understanding of global compliance standards for all entities in the prednisone supply chain.

How do raw material sourcing and cost pressures impact prednisone supply?

The cost of producing prednisone API is influenced by the availability and price fluctuations of key starting materials and intermediate chemicals. The supply chain for these precursors can be complex and is often global.

• Steroid Precursors: Prednisone is a synthetic corticosteroid. Its synthesis typically begins with steroid precursors, often derived from plant sterols (e.g., diosgenin from yams, stigmasterol from soybeans) or through complex multi-step chemical synthesis. The availability and cost of these natural sources or the efficiency of synthetic routes are critical cost drivers.
• Chemical Reagents and Solvents: The multi-step synthesis of prednisone requires various chemical reagents and solvents. Fluctuations in the global market prices of these commodity chemicals, driven by petrochemical prices, supply/demand imbalances, or geopolitical events, can directly impact API production costs.
• Energy Costs: Chemical synthesis is an energy-intensive process. Rising energy prices in manufacturing regions can increase production costs for both API and excipients.
• Labor Costs: While API manufacturing in India and China has historically benefited from lower labor costs compared to Western countries, wage inflation in these regions can gradually increase manufacturing expenses.
• Environmental Regulations: Increasingly stringent environmental regulations in major API manufacturing countries can necessitate investments in pollution control technologies, increasing capital and operational expenditures, which may be passed on as higher prices.
• Logistics and Transportation: Global supply chains are subject to freight costs, port congestion, and fuel surcharges, all of which add to the final cost of delivered API and finished products.

These factors contribute to a competitive pricing environment for generic prednisone. Manufacturers must manage their raw material sourcing strategically, maintain efficient production processes, and navigate global cost pressures to ensure a stable and cost-effective supply.

What are the key risks and vulnerabilities in the prednisone supply chain?

The global nature of prednisone manufacturing and its reliance on specific geographic regions and a limited number of large-scale producers create several potential risks and vulnerabilities.

• Geographic Concentration: Over-reliance on India and China for API production makes the supply chain susceptible to localized disruptions. These can include:
  • Natural Disasters: Earthquakes, floods, or pandemics affecting production facilities or transportation networks.
  • Geopolitical Instability: Trade disputes, export restrictions, or political unrest in manufacturing countries.
  • Regulatory Enforcement Actions: Increased scrutiny or shutdowns of manufacturing plants due to environmental or quality compliance issues.
• Single-Source Dependencies: For specific excipients or starting materials, there may be a limited number of qualified suppliers. A disruption at one of these suppliers can have a ripple effect across multiple FDF manufacturers.
• Quality Control Failures: Any lapse in quality control at an API or excipient manufacturing site can lead to product recalls, regulatory actions, and significant supply interruptions. Maintaining consistent quality across global manufacturing networks is a continuous challenge.
• Intellectual Property and Generic Competition: While prednisone is a well-established drug with expired patents, process innovation in API synthesis can still provide competitive advantages. However, the primary risk lies in the commoditized nature of the market, where price is a major determinant of market share.
• Logistical Challenges: Global shipping delays, port congestion, and increasing freight costs can impact the timely delivery of both raw materials and finished products, leading to stockouts or increased inventory holding costs.
• Supply Chain Transparency and Traceability: Ensuring full visibility and traceability throughout the complex multi-tier supply chain can be challenging, making it difficult to identify and mitigate risks proactively.

Mitigating these risks requires diversified sourcing strategies, robust supplier qualification and monitoring programs, adequate inventory management, and continuous engagement with regulatory bodies and industry partners.

Key Takeaways

• Prednisone API manufacturing is dominated by a concentrated group of suppliers primarily located in India and China.
• Critical excipients for prednisone formulations, such as lactose, microcrystalline cellulose, povidone, and magnesium stearate, are supplied by a mix of global and regional manufacturers with generally robust supply.
• Strict adherence to cGMP, pharmacopeial standards, and impurity profiling is mandated by global regulatory agencies for both API and finished drug products.
• The cost of prednisone production is sensitive to raw material prices, energy costs, labor, and environmental compliance expenses, influencing the competitive pricing of generic formulations.
• Key supply chain vulnerabilities include geographic concentration of API production, potential single-source dependencies for certain excipients, quality control failures, and logistical disruptions.

Frequently Asked Questions

1. Are there any upcoming patent expirations relevant to prednisone manufacturing processes? Prednisone itself is a long-established drug with patents that expired decades ago. The focus for patentability in this area typically shifts to novel manufacturing processes, polymorphic forms, or improved drug delivery systems, rather than the active molecule itself.
2. What is the typical lead time for procuring prednisone API from major suppliers? Lead times can vary significantly based on current demand, supplier production schedules, and order volume, but typically range from 8 to 16 weeks for bulk API orders.
3. How do regulatory changes in China or India typically impact prednisone API availability? Stricter enforcement of environmental regulations or quality standards in these major manufacturing hubs can lead to temporary plant shutdowns or reduced output, potentially causing short-term supply shortages and price increases for prednisone API.
4. What recourse do pharmaceutical companies have if a key prednisone API supplier experiences a significant quality issue? Companies are required to have pre-qualified alternative suppliers. If a primary supplier fails, they must rapidly switch to a qualified secondary source, which involves re-validation and regulatory notification, potentially causing temporary stockouts.
5. Are there any readily available, non-Chinese/Indian sources for prednisone API if supply from those regions is disrupted? While some API manufacturing exists in other regions, the scale and cost-competitiveness for high-volume generics like prednisone are significantly lower. Diversification to other regions for comparable scale and cost is challenging and would likely involve higher per-unit costs.

Citations

[1] U.S. Food and Drug Administration. (2019). Drug Shortages: Root Causes and Potential Solutions. Retrieved from [URL placeholder for FDA report on API sourcing - specific URL needs to be researched if this is for a real publication] (Note: Specific report citation needed for accuracy)